Emergence of Linezolid Resistance in a Methicillin Resistant Staphylococcus aureus Strain

Hentschke, M.; Saager, B.; Horstkotte, Matthias A.; Scherpe, Stefanie; Wolters, Manuel; Kabisch, H; Grosse, R.; Heisig, Peter; Aepfelbacher, Martin; Rohde, Holger

doi:10.1007/s15010-007-7220-7

Cited by 35 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mupirocin (Bactroban)-based ointments, one of the recommended treatments for Staphylococcus aureus-induced SSTIs, are losing their effectiveness, especially against antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA) (3,4). Increased resistance to vancomycin and linezolid, considered "drugs of last resort" for severe MRSA and vancomycin-resistant S. aureus infections, respectively, has also been reported (5)(6)(7)(8). This further limits treatment options for S. aureus-induced SSTIs, especially those caused by antibiotic-resistant strains, and alternatives are desperately needed to ensure future treatment efficacy.…”

mentioning

confidence: 99%

Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored byIn VivoBioluminescent Imaging

Staden

Heunis

Smith

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

c Staphylococcus aureus is a bacterial pathogen responsible for the majority of skin and soft tissue infections. Antibiotics are losing their efficacy as treatment for skin and soft tissue infections as a result of increased resistance in a variety of pathogens, including S. aureus. It is thus imperative to explore alternative antimicrobial treatments to ensure future treatment options for skin and soft tissue infections. A select few lantibiotics, a group of natural defense peptides produced by bacteria, inhibit the growth of numerous clinical S. aureus isolates, including methicillin-resistant strains. In this study, the antimicrobial activities of nisin, clausin, and amyloliquecidin, separately administered, were compared to that of a mupirocin-based ointment, which is commonly used as treatment for S. aureus-induced skin infections. Full-thickness excisional wounds, generated on the dorsal surfaces of mice, were infected with a bioluminescent strain of S. aureus (strain Xen 36). The infections were monitored in real time using in vivo bioluminescent imaging. Lantibiotic treatments significantly reduced the bioluminescence of S. aureus Xen 36 to a level similar to that recorded with mupirocin treatment. Wound closure, however, was more pronounced during lantibiotic treatment. Lantibiotics thus have the potential to be used as an alternative treatment option for S. aureus-induced skin infections.

show abstract

mentioning

confidence: 99%

Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored byIn VivoBioluminescent Imaging

Staden

Heunis

Smith

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Newer antibiotics, such as linezolid, are alternatives in the treatment of severe infections caused by multidrug-resistant staphylococci. In the last few years, linezolid-resistant staphylococci, mainly in patients undergoing prolonged therapy, have been reported (4,5,13). The most common mechanism of linezolid resistance involves mutations in the 23S rRNA gene.…”

mentioning

confidence: 99%

Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in Spain

Betriú

Morales

Rodríguez-Avial

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC 50 and MIC 90 values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 g/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.

show abstract

“…The emergence of vancomycin resistance, which was first documented in 1996 in Japan, has since been encountered in the USA, the UK and Brazil, among several other countries, and is indeed a worrying progression of bacterial evolution [7,8]. While linezolid, daptomycin and other last-resort agents are still effective even against vancomycinresistant strains, early reports of new linezolid-resistant strains have already emerged, which are alarming at the very least [9].…”

Section: Notable Microbesmentioning

confidence: 99%

Controversies in host defense against surgical site infection

Qadan¹,

Cheadle²

2009

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Emergence of Linezolid Resistance in a Methicillin Resistant Staphylococcus aureus Strain

Cited by 35 publications

References 17 publications

Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored byIn VivoBioluminescent Imaging

Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored byIn VivoBioluminescent Imaging

Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in Spain

Controversies in host defense against surgical site infection

Contact Info

Product

Resources

About